A new review of GLP-1 receptors and cancer brings together an intriguing possibility: medicines developed for metabolic disease might also influence how tumors grow or how immune cells respond to them. The useful question is how far those experiments have traveled toward evidence that could help a person with cancer.
So far, the two original studies examined here offer clues from mice and laboratory experiments, not demonstrated cancer-treatment benefits in patients. The review by Jing and colleagues appeared online on 27 October 2026 according to the publisher; PubMed lists 30 October. It synthesizes earlier work rather than reporting a new patient trial.
What the review adds to the question
The authors describe possible effects on cell growth, inflammation, immune activity and signaling pathways inside cells. They also discuss conflicting findings about cancer risk and differences in where GLP-1 receptors are detected. This is a broad map of hypotheses, not one consistent result across every medicine or cancer type.
Its scope needs particular care: the review covers prescription GLP-1 receptor agonists alongside several natural compounds discussed for related biological activity. Findings about one compound cannot be transferred to another simply because they appear in the same review. Nor does a cell experiment become a clinical result when it is included in a discussion of potential treatments.
A semaglutide experiment points toward immune activity
In one original study published in 2024, researchers tested semaglutide in a 4T1 breast-tumor model in BALB/C mice. The abstract reports slower tumor development and growth, alongside changes involving dendritic cells and T cells, which participate in immune responses.
A revealing detail is that semaglutide did not show a direct cell-killing effect in the laboratory assay described. The investigators instead proposed that changes in the acquired immune response helped explain their findings. That distinction matters: “a tumor grew more slowly in this mouse model” is a narrower conclusion than “semaglutide kills breast cancer.”
Only the abstract and indexed publication record were inspected for this study. They do not supply enough detail here to judge all group sizes, exposure schedules or numerical effect estimates. The mice received experimental injections into the abdominal cavity; this is not a regimen for people to reproduce. Our semaglutide profile addresses the medicine’s clinical context separately.
A second study asks about combination treatment
A liraglutide study in FEBS Open Bio explored a different question: could it influence the response to an experimental anti-PD-1 immune-checkpoint treatment? Researchers used male mice bearing lung- or liver-tumor models and compared control, liraglutide, anti-PD-1 and combination groups over a two-week treatment period.
The authors reported stronger antitumor effects with the combination and investigated neutrophil extracellular traps, often shortened to NETs. These are web-like structures released by a type of immune cell. The proposed mechanism involved reducing these traps and reactive oxygen species around tumors, potentially changing the immune response.
This was still an animal experiment. The full paper contains inconsistencies in some figure captions and descriptions of statistical tests, so detailed effect sizes are not reproduced here. Neither its findings nor the semaglutide abstract establishes that adding a GLP-1 medicine to cancer therapy improves patient survival, symptoms or quality of life. The two experiments also cannot rank liraglutide against semaglutide: they used different tumors, designs and treatment combinations.
Cancer risk and cancer treatment are different outcomes
Three questions can become blurred in a headline. Does a medicine change a biological pathway? Are people taking it more or less likely to receive a cancer diagnosis? Does it improve outcomes after cancer has developed? These studies principally address the first question and experimental tumor behavior.
A human observational association would not, by itself, answer the treatment question either. Differences in health, medicine selection and follow-up can influence comparisons. Our guide to randomized and real-world evidence explains why the design and comparison group matter.
Promising mechanisms also do not cancel established precautions. The current US Wegovy prescribing information does not list cancer treatment as an indication. It retains a boxed warning about thyroid C-cell tumors in rodents, with unknown relevance to humans, and contraindications involving medullary thyroid carcinoma or MEN2. Our thyroid-warning guide explains those distinctions without treating all thyroid disease as the same condition.
What would make the next finding more useful?
The important next step is evidence in a clearly defined patient population, with an appropriate comparison, adequate follow-up and outcomes that matter to patients. Safety alongside existing cancer care would need evaluation too. Our guide to reading trials offers a framework for checking population, endpoint and duration.
For now, this review helps identify research questions. It does not provide a reason to start, stop or switch a medicine for cancer prevention or treatment. When the next headline arrives, look for the species studied, the specific drug and cancer, and whether the result concerns a laboratory marker or an actual patient outcome.



